title: Prospective evaluation of the utility of molecular techniques for diagnosing nosocomial transmission of multidrug-resistant tuberculosis.
abstract: OBJECTIVE
  To compare molecular techniques with conventional diagnostic methods for evaluating nosocomial transmission of multidrug-resistant tuberculosis (MDR-TB).
  
  
  METHODS
  We conducted a 12-week postexposure inception cohort study of health-care personnel who had been exposed to a patient with MDR-TB.
  
  
  METHODS
  In addition to baseline and follow-up tuberculin skin tests and chest roentgenography, weekly pulmonary specimens were evaluated by (1) auramine-rhodamine fluorescent staining, (2) culture for mycobacteria, and (3) polymerase chain reaction (PCR) to amplify IS6110, a nucleic acid insertion sequence unique to the Mycobactrium tuberculosis complex.
  
  
  RESULTS
  The index patient's isolate of M. tuberculosis showed a mutation in codon 531 of the RNA polymerase beta subunit (rpoB) gene of M. tuberculosis, which is associated with rifampin resistance and considered a marker for this MDR-TB strain. All pulmonary and gastric specimens from study participants had negative auramine stains and cultures for mycobacteria, One person, however, had separate specimens with repeatedly positive PCR results for IS6110 sequences, but the specimens contained a wild-type M. tuberculosis rpoB codon 531 dissimilar from the index patient's strain.
  
  
  CONCLUSIONS
  Although both molecular and conventional testing showed that no exposed person was infected with the MDR-TB strain, molecular test results were available sooner and seemed more sensitive for detecting M. tuberculosis in one exposed person, presumably in a preinfection or "colonized" stage. Molecular methods provided information that helped distinguish this person's M. tuberculosis strain from the index patient's MDR-TB strain. Additional prospective studies should assess the value of these molecular techniques in similar clinical settings.
authors.affiliation: Division of Clinical Microbiology, Mayo Clinic Rochester, Rochester, Minnesota 55905 USA.
authors.forename: F R
authors.initials: FR
authors.lastname: Cockerill
authors.forename: D E
authors.initials: DE
authors.lastname: Williams
authors.forename: K D
authors.initials: KD
authors.lastname: Eisenach
authors.forename: B C
authors.initials: BC
authors.lastname: Kline
authors.forename: L K
authors.initials: LK
authors.lastname: Miller
authors.forename: L
authors.initials: L
authors.lastname: Stockman
authors.forename: J
authors.initials: J
authors.lastname: Voyles
authors.forename: G M
authors.initials: GM
authors.lastname: Caron
authors.forename: S K
authors.initials: SK
authors.lastname: Bundy
authors.forename: G D
authors.initials: GD
authors.lastname: Roberts
authors.forename: W R
authors.initials: WR
authors.lastname: Wilson
authors.forename: A C
authors.initials: AC
authors.lastname: Whelen
authors.forename: J M
authors.initials: JM
authors.lastname: Hunt
authors.forename: D H
authors.initials: DH
authors.lastname: Persing
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use; D001483:Base Sequence; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D004269:DNA, Bacterial / Q000032:analysis; D005069:Evaluation Studies as Topic; D006801:Humans; D017758:Infectious Disease Transmission, Patient-to-Professional / Q000032:analysis; D008969:Molecular Sequence Data; D009169:Mycobacterium tuberculosis / Q000235:genetics / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000188:drug therapy / Q000635:transmission*
chemical_list: D000995:Antitubercular Agents; D004269:DNA, Bacterial